BioSpace News Archive

Biofourmis, a fast-growing global leader in digital therapeutics based in Boston, announced today it has been selected by Novartis, a global healthcare company, to collaborate on a commercial project for managing patients with heart failure (HF) beginning in Southeast Asia, with potential plans to expand globally.

Acquisition to Expand Alkermes’ Presence in CNS to a Wide Range of Neurodegenerative Diseases Through Epigenetic Control of Synaptogenesis

Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical stage immuno-oncology company, today announced that it will host a lunchtime seminar led by key opinion leaders (“KOL”'s) to highlight the current treatment options for recurrent glioblastoma (“rGBM”) and the clinical benefits seen with MDNA55, an IL4 receptor targeted therapy in this setting.

Forbius, a clinical-stage protein engineering company that develops biotherapeutics to treat fibrosis and cancer, announced today that Forbius management will present a company overview at the Jefferies 2019 Healthcare Conference on Thursday, November 21, 2019 at 07:20 a.m. GMT in London.

BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) announced today that enrollment and randomization of 12,463 participants in the pivotal, clinical efficacy, Phase 3 trial of the M-001 universal influenza vaccine candidate is complete.

SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that the Canadian Department of National Defence (CDND) has issued an advanced contract award notice (ACAN), indicating that it intends to award a contract to fund regulatory filing with Health Canada for approval of oral TPOXX®.

Tauriga Sciences, Inc. confirmed that it will be an Exhibitor at The CBD.io Expo 2019, which will take place on November 22-23, 2019 at the following venue: The Las Vegas Convention Center / Las Vegas, Nevada.

Liminal BioSciences Inc. (NASDAQ: LMNL) (TSX: LMNL) (“Liminal BioSciences” or the “Company”), a clinical-stage biotechnology company focused on developing novel therapeutics to treat unmet needs in patients with liver, respiratory and kidney disease, announced today that its registration statement on Form F-10

H-CYTE Inc. (OTCQB: HCYT) the owner and operator of innovative medical technology products and services including LungCYTE and Lung Health Institute, announces it has raised $6 million in new funding.

Cidara Therapeutics, Inc., a biotechnology company developing novel anti-infectives including immunotherapies, announced that it has been named a Top Workplace by The San Diego Union-Tribune for the third consecutive year.